51-75-2

Usage

Uses

Used in Anticancer Applications:
Chlormethine is used as an antineoplastic agent for the treatment of cancer. It has been employed in chemotherapy, particularly against solid malignancies, due to its ability to interfere with cell division and DNA synthesis in cancer cells.
Used in Chemical Warfare:
Chlormethine, under the military designation HN-2, was formerly used as a gas warfare agent. However, its use in this context is now highly restricted, and there are no current records of its use for this purpose.
Used in Pharmaceutical Industry:
Chlormethine is used in the pharmaceutical industry under the brand name Mustargen (Ovation) as a drug for the treatment of cancer. Its application in this industry is focused on its antineoplastic properties, which make it a valuable compound in the fight against various types of cancer.

Production Methods

The nitrogen mustards are tertiary amines in which the halogen atom and the amine portion have reactivities similar to those of alkyl halides and alkyl amines. They are oily liquids that have limited water solubility but form readily soluble hydrochlorides. They are prepared by the action of thionyl chloride on the appropriate alkanolamine. Many of the actions of the nitrogen mustards resemble those of ethyleneimine derivatives because they are transformed in aqueous solutions into the highly reactive ethylenimonium intermediates: these ions can readily react with a variety of organic compounds in vitro, especially with amino, sulfhydro, and carboxyl groups of proteins and phosphate groups in nucleic acid, and therefore can alkylate biologically important macromolecules.

Reactivity Profile

Chlormethine is a chlorinated amine. Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.

Hazard

Strong irritant to tissues, lachrymatory. Probable carcinogen.

Health Hazard

Toxic doses as low as 400 mg/kg have been reported in humans. Blood clots may occur at site of intravenous injection and tissue damage if outside vein. Powerful vesicant (causes blisters) when it contacts skin, mucous membranes, or eyes. Delayed toxicity -- missed menstrual periods, alopecia (hair loss), hearing loss, tinnitus (ringing in ears), jaundice, impaired spermatogenesis and germinal aplasia, swelling, and hypersensitivity. May damage fetus in pregnant women.

Fire Hazard

Undiluted liquid decomposes on standing.

Safety Profile

Confirmed human carcinogenproducing skin tumors by skin contact. Experimentalcarcinogenic, tumorigenic, and neoplastigenic data. Adeadly poison by inhalation, ingestion, skin contact, andmost other routes. Experimental teratogenic andreproductive eff

Potential Exposure

Drug used in treatment of cancer. Exposure to nitrogen mustard damages the eyes, skin, and respiratory tract and suppresses the immune system. Although the nitrogen mustards cause cellular changes within minutes of contact, the onset of pain and other symptoms is delayed. Exposure to large amounts can be fatal. Sulfur mustards were formerly used as a gas warfare agent. Nitrogen mustards have not previously been used in warfare

Shipping

UN2810 Toxic liquids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required. Military driver shall be given full and complete information regarding shipment and conditions in case of emergency. AR 50-6 deals specifically with the shipment of chemical agents. Shipments of agent will be escorted in accordance with AR 740-32

Incompatibilities

HN-2 is not stable except as dry crystals. Polymerization of HN-2 results in components that present an explosion hazard in open air. Avoid contact or contamination with oxidizers e.g., nitrates, oxidizing acids; chlorine bleaches pool chlorine); which may result in ignition. Unstable in the presence of light and heat and forms dimers at temperatures above 50C. Corrosive to ferrous alloys beginning @ 65C. Polymerizes slowly, so munitions would be effective for several years. Heated to decomposition emits hydrogen chloride and nitrogen oxide. Contact with metals may evolve flammable hydrogen gas. Note: Chlorinating agents destroy nitrogen mustards. Dry chlorinated lime and chloramines with a high content of active chlorine vigorously chlorinate nitrogen mustards to the carbon chain, giving low toxicity products. In the presence of water this interaction proceeds less actively. They are rapidly oxidized by peracids in aqueous solution at weakly alkaline pH. In acid solution the oxidation is much slower.An amine and a chemical base: will neutralize acids to form salts plus water with an exothermic reaction. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents such as hydrides, nitrides, alkali metals, and sulfides

Waste Disposal

It is inappropriate and possibly dangerous to the environment to dispose of expired or waste drugs and pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged, and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator

InChI:InChI=1/C5H11Cl2N/c1-4(6)8(3)5(2)7/h4-5H,1-3H3

Upstream product

• 105-59-9 N-Methyldiethanolamine 
• 92204-31-4 Bis-(2-chloroethyl)-ethoxymethylammonium 
• 1346936-27-3 N, N-bis(2-chloroethyl)-N-methyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl] methanaminium bromide 
• 1346936-29-5 N,N-bis(2-chloroethyl)-N-methyl-N-(4-boronophenyl)methanaminium bromide 
• 1346936-32-0 N,N-bis(2-hydroxyethyl)-N-methyl-N-[4-(6-methyl-1,3,6,2-dioxazaborocan-2-yl)phenyl]methanaminium bromide 
• 50-00-0 formaldehyd 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 92336-62-4 Ethoxy-bis(2-hydroxyethyl)methylammonium 
• 55-86-7 mechlorethamine hydrochloride 

Downstream Products

• 109156-90-3 methyl-bis-(3-[2]pyridyl-propyl)-amine 
• 109154-88-3 methyl-bis-(3-[3]pyridyl-propyl)-amine 
• 121970-60-3 methyl-bis-[2-(phenyl-piperidino-acetoxy)-ethyl]-amine 
• 3627-62-1 1-methyl-4-phenyl-piperidine-4-carbonitrile 
• 855639-22-4 4-(3,4-dimethyl-phenyl)-1-methyl-piperidine-4-carbonitrile 
• 75161-66-9 4-(3,4-dimethoxy-phenyl)-1-methyl-piperidine-4-carbonitrile 
• 5460-79-7 1-methyl-4-(m-methoxyphenyl)-4-cyanopiperidine 
• 408510-18-9 4-(2-methoxy-phenyl)-1-methyl-piperidine-4-carbonitrile 
• 408510-36-1 4-(2,3-dimethoxy-phenyl)-1-methyl-piperidine-4-carbonitrile 
• 860114-04-1 4-(2-benzyloxy-phenyl)-1-methyl-piperidine-4-carbonitrile 

Relevant academic research and scientific papers

Synthesis and cytotoxicity of pyridine and quinoline oxorhenium(V) complexes with tridentate (NS2, S3)/monodentate (S) coordination

New oxorhenium complexes with tridentate 3-thia- and 3-methylazapentane-1, 5-dithiolate and monodentate pyridine and quinoline derivatives have been synthesized. As a result of investigation of biological activity a high cytotoxicity was found for the synthesized complexes in relation to tumor cells. The specificity of the 2-pyridylthiolato[3-(N-methyl)azapentane-1,5-dithiolato] oxorhenium(V) cytotoxic action towards cells of mouse hepatoma MG-22A on a background of low acute toxicity was established.

Rational design of an organocatalyst for peptide bond formation

Amide bonds are ubiquitous in peptides, proteins, pharmaceuticals, and polymers. The formation of amide bonds is a straightforward process: amide bonds can be synthesized with relative ease because of the availability of efficient coupling agents. However, there is a substantive need for methods that do not require excess reagents. A catalyst that condenses amino acids could have an important impact by reducing the significant waste generated during peptide synthesis. We describe the rational design of a biomimetic catalyst that can efficiently couple amino acids featuring standard protecting groups. The catalyst design combines lessons learned from enzymes, peptide biosynthesis, and organocatalysts. Under optimized conditions, 5 mol % catalyst efficiently couples Fmoc amino acids without notable racemization. Importantly, we demonstrate that the catalyst is functional for the synthesis of oligopeptides on solid phase. This result is significant because it illustrates the potential of the catalyst to function on a substrate with a multitude of amide bonds, which may be expected to inhibit a hydrogen-bonding catalyst.

Utilisation of new NiSNS pincer complexes in paraffin oxidation

Two series of closely related SNS pincer ligands (L) were synthesised with the major structural variation on the nitrogen backbone containing either the methyl [L = (RSCH2CH2)2NMe: where R = Me (1), Et (2), Bu (3)] or the phenyl [L = (RSCH2CH2)2NPh: where R = Me (4), Et (5), Cy (6)] functional group. When ligands 1–3 were complexed to Ni by reaction with Ni(DME)Cl2 (DME = dimethoxyethane), they respectively yielded three new cationic dimeric [LNi(μ-Cl)3NiL]+ complexes (7–9), whilst ligands 4–6 on reaction with Ni(PPh3)2Br2 respectively yielded neutral mononuclear (LNiBr2) complexes 10–12. All the new compounds were characterised by IR, HRMS, elemental analysis and in addition, single crystal X-ray diffraction for complexes 9–12. X-ray structural data of 9 revealed an unusual three chlorido-bridged Ni dimer with the SNS ligand coordinated in a facial binding mode to the two pseudo-octahedral Ni centres. Molecular structures of complexes 10, 11 and 12 each displayed five-coordinate distorted trigonal bipyramidal geometry around the nickel(II) metal centres. When utilised as catalysts in the tert-butyl hydroperoxide oxidation of n-octane, all the complexes showed activity to mainly products of internal carbon activation (octanones and secondary octanols) with 11 as the most active (10% total substrate to oxygenates yield), whereas 10 was the least active, but most selective towards alcohols (alcohol/ketone = 2.13).

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

THERAPEUTIC FOR HEPATIC CANCER

A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.

SPECIFIC BINDING PROTEINS AND USES THEREOF

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Hydrogen peroxide inducible DNA cross-linking agents: Targeted anticancer prodrugs

The major concern for anticancer chemotherapeutic agents is the host toxicity. The development of anticancer prodrugs targeting the unique biochemical alterations in cancer cells is an attractive approach to achieve therapeutic activity and selectivity. We designed and synthesized a new type of nitrogen mustard prodrug that can be activated by high level of reactive oxygen species (ROS) found in cancer cells to release the active chemotherapy agent. The activation mechanism was determined by NMR analysis. The activity and selectivity of these prodrugs toward ROS was determined by measuring DNA interstrand cross-links and/or DNA alkylations. These compounds showed 60-90% inhibition toward various cancer cells, while normal lymphocytes were not affected. To the best of our knowledge, this is the first example of H 2O2-activated anticancer prodrugs.

Linear cationic click polymer for gene delivery: Synthesis, biocompatibility, and in Vitro Transfection

Sixteen novel cationic click polymers (CPs) were parallelly synthesized via the conjugation of four alkyne- functionalized monomers to four azide-functionalized monomers by "click chemistry". The biocompatibility of CPs was evaluated by in vitro cytotoxicity (MTT assay, Hoechst/PI apoptosis/necrosis assay, and cell cycle analysis) and blood compatibility tests (hemolysis and erythrocyte aggregation). The experimental results showed that the kind of amine groups, charge density, and number of methylene or ethylene glycol groups brought about the effect on toxicity of CPs. Among all polymers, two polymers (B1 and B2) showed good biocompatibility, inducing neither apoptosis nor necrosis at the test concentration and low hemolysis ratio and erythrocyte aggregation. In particular, B1 and B2 exhibited the comparable transfection efficiency compared with PEI (25 kDa) but much lower cytotoxicity. These results suggested that the novel cationic CPs could be promising carriers for gene delivery.

Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same

Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.

Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy) alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives

A series of pyridylimidazolidinone derivatives was synthesized and tested in vitro against enterovirus 71 (EV71). On the basis of compound 33 (DBPR103), introduction of a methyl group at the 2- or 3-position of the linker between the imidazolidinone and the biphenyl resulted in markedly improved antiviral activity toward EV71 with IC50 values of 5.0 nM (24b) and 9.3 nM (14a), respectively. Increasing the branched chain to propyl resulted in a progressive decrease in activity, while inserting different heteroatoms entirely rendered the compound only weakly active. The introduction of a bulky group (cyclohexyl, phenyl, or benzyl) led to loss of activity against EV71. The 4-chlorophenyl moiety in 14a was replaced with bioisosteric groups such as oxadiazole (28a-d) or tetrazole (32a,b), dramatically improving anti-EV71 activity and selectivity indices. Compounds 14a, 24b, 28b, 28d, and 32a exhibited a strong activity against lethal EV71, and no apparent cellular toxicity was observed. Three of the more potent imidazolidinone compounds, 14a, 28b, and 32b, were subjected to a large group of picornaviruses to determine their spectrum of antiviral activity.